



September 25, 2023

Name of Company: Meiji Holdings Co., Ltd.  
Name of Representative: Kazuo Kawamura, CEO, President and Representative Director  
Code Number: 2269, Prime Market, Tokyo Stock Exchange

**Notice concerning Approval in Japan for Marketing Authorization of  
“Quintovac Aqueous Suspension Injection”,  
Diphtheria, Pertussis, Tetanus, Inactivated Polio and Hib  
Five-in-One Combination Vaccine**

Meiji Holdings Co., Ltd. announced that its subsidiary KM Biologics Co., Ltd. (“KM Biologics”) received marketing authorization approval in Japan for the combination vaccine “Quintovac Aqueous Suspension Injection” (the “Vaccine”) from the Ministry of Health, Labour and Welfare (MHLW) today. The Vaccine is a five-in-one combination vaccine for preventing infectious diseases caused by diphtheria, pertussis, tetanus, acute poliomyelitis (polio), and *Haemophilus influenzae* type b (Hib).

The Vaccine adds the Hib antigen to the “Quattrovac® S.C. Injection Syringe”, a combination vaccine against diphtheria, pertussis, tetanus, and polio. The Hib antigen was developed by KM Biologics, and all antigens used in the Vaccine are manufactured domestically.

KM Biologics has developed the Vaccine in response to the MHLW’s request from 2013 to develop vaccines with high priority. The Vaccine is expected to reduce the number of routine vaccination shots for infants, thus reducing the burden on infants and their guardians.

The impact of this matter on consolidated earnings forecasts for the fiscal year ending March 31, 2024 is expected to be minor.

#####